Learn how the Sarnat score interprets neonatal encephalopathy staging. Understand severity levels, diagnosis, and next steps for your baby’s care in this clear guide.
By Shubhra Mishra — a mom of two who turned her own confusion during pregnancy into BumpBites, a global mission to make food choices clear, safe, and stress-free for every expecting mother. 💛
Check whether any food is safe during pregnancy with the BumpBites Food Safety Checker.
Download the Complete Pregnancy Food Guide (10,000 Foods) 📘
Instant PDF download • No spam • Trusted by thousands of moms
💡 Your email is 100% safe — no spam ever.
Quick take: The Sarnat score is a bedside tool that grades neonatal encephalopathy into three stages—mild (Stage 1), moderate (Stage 2), and severe (Stage 3)—based on neurologic exam, seizures, and autonomic function. It guides treatment, predicts short‑ and long‑term outcomes, and helps clinicians decide whether therapeutic hypothermia is indicated.
It’s 2 a.m., you’ve just been told your newborn’s Apgar is lower than expected, and the neonatology team mentions a “Sarnat score.” Your heart races. You wonder: what does that number really mean for my baby’s future? You’re not alone. Many parents encounter the term during the first critical hours after birth, and the jargon can feel overwhelming.
In this article we’ll demystify the Sarnat score—what it measures, how each stage looks, how clinicians arrive at a number, and what that number means for treatment and long‑term development. We’ll also compare it with other scoring systems, bust common myths, and give you clear next‑step questions to ask your provider. By the end, you’ll have a solid, doctor‑approved foundation to discuss your baby’s care with confidence.
What is the Sarnat score and why it matters?
The Sarnat score, formally called the Sarnat‑Sarnat staging system, was introduced in 1976 by Drs. Harvey Sarnat and Joseph Sarnat to classify the severity of hypoxic‑ischemic encephalopathy (HIE) in newborns. HIE occurs when the brain does not receive enough oxygen and blood around the time of birth, leading to a spectrum of neurologic injury.
Why clinicians still rely on this decades‑old tool is simple: it uses readily observable clinical signs—muscle tone, reflexes, level of consciousness, seizure activity, and autonomic function (heart rate, breathing, temperature)—to assign a stage that correlates with the need for urgent neuroprotective therapy, most commonly whole‑body therapeutic hypothermia.
Guidelines from the American College of Obstetricians and Gynecologists (ACOG), the National Institute for Health and Care Excellence (NICE), and the World Health Organization (WHO) all reference the Sarnat staging when recommending therapeutic hypothermia for infants with moderate or severe encephalopathy. In short, the score helps decide whether a baby should receive a life‑saving treatment and gives families an early, evidence‑based prognosis.
Neonatal clinicians assess the Sarnat score bedside, often within the first six hours of life.
Beyond immediate treatment decisions, the Sarnat score serves as a common language across neonatal units worldwide. When a neonatologist says “Stage 2,” every team member—from the bedside nurse to the radiologist—understands the expected physiologic challenges and the urgency of interventions. This shared language also facilitates research collaborations and quality‑improvement initiatives, ensuring that babies receive consistent care regardless of the hospital they are born in.
How the Sarnat stages are defined: mild, moderate, and severe
Each stage of the Sarnat score reflects a distinct pattern of neurologic and autonomic findings. Below is a detailed breakdown of what you might see at the bedside for each stage.
Stage 1 (Mild encephalopathy)
Consciousness: The infant is alert or mildly irritable but can be easily aroused.
Muscle tone: Slightly increased (hypertonia) or normal; there is no flaccidity.
Reflexes: Hyperreflexia, especially the Moro (startle) reflex, may be exaggerated.
Seizures: No clinical seizures; electroencephalogram (EEG) is typically normal.
Autonomic function: Heart rate, respiration, and temperature are stable; occasional mild apnea may occur.
Prognosis: Most infants recover fully with minimal or no neurodevelopmental impairment.
Because the signs are subtle, clinicians often repeat neurologic checks every few hours to ensure the baby does not slip into a higher stage. Parents are reassured that the majority of mild cases resolve without lasting effects, but they are still encouraged to attend all scheduled developmental screenings.
Stage 2 (Moderate encephalopathy)
Consciousness: Lethargic; the infant is difficult to arouse and may have a decreased response to stimuli.
Muscle tone: Variable—often a combination of hypertonia and hypotonia; the infant may be floppy in the limbs but stiff in the trunk.
Seizures: Clinical seizures are common (up to 30–40 % of moderate cases) and may be subtle, such as eye‑blinking or lip‑smacking.
Autonomic function: Tachycardia or bradycardia, irregular breathing patterns, and temperature instability are frequent.
Prognosis: With timely therapeutic hypothermia, many infants achieve normal development, though a minority may develop mild motor or cognitive delays.
Stage 2 is the threshold at which therapeutic hypothermia is strongly recommended. The treatment window is narrow—ideally within six hours of birth—because cooling works by interrupting the cascade of cellular injury that begins minutes after the hypoxic event.
Stage 3 (Severe encephalopathy)
Consciousness: Comatose; the infant is unresponsive to painful stimuli.
Muscle tone: Marked hypotonia (floppiness) or, paradoxically, severe hypertonia with decorticate or decerebrate posturing.
Reflexes: Absent or severely depressed reflexes, including the Moro and gag reflexes.
Seizures: Frequent, often refractory clinical seizures; EEG typically shows burst‑suppression or other severe patterns.
Autonomic function: Profound instability—persistent bradycardia, apnea, and temperature dysregulation (often hypothermia despite environmental warmth).
Prognosis: Even with hypothermia, the risk of severe neurodevelopmental impairment, cerebral palsy, or death is high.
Because the brain injury is extensive, clinicians focus on preventing secondary damage while preparing families for long‑term care planning. Early involvement of social workers, rehabilitation specialists, and palliative care teams is common in this stage.
These clinical hallmarks are assessed during the first 24 hours of life, ideally within the first 6 hours, because early identification of moderate or severe HIE is essential for initiating hypothermia within the therapeutic window.
How clinicians calculate the Sarnat score in a newborn
The Sarnat score is not a numeric sum like some other scales; instead, it is a categorical staging based on a checklist of findings. Neonatologists and neonatal nurses perform a systematic neurologic exam that includes:
Level of consciousness (alert, lethargic, stuporous, comatose).
Muscle tone (normal, hypertonic, hypotonic, mixed).
Reflexes (Moro, grasp, plantar responses).
Presence and type of seizures (none, subtle, overt).
Autonomic signs (heart rate, respiratory pattern, temperature regulation).
Each domain is compared against the stage definitions above. If any single domain meets the criteria for Stage 3, the infant is classified as severe (Stage 3). If no domains meet Stage 3 criteria but at least one meets Stage 2 criteria, the infant is staged as moderate (Stage 2). Otherwise, the infant is placed in the mild category (Stage 1).
Because the assessment is time‑sensitive, many centers use a standardized worksheet that records each finding with a tick box. The worksheet is then reviewed by the attending neonatologist, who confirms the stage. For parents who want to understand how the numbers are derived, the Sarnat HIE Staging calculator on our site walks you through each sign and automatically generates the appropriate stage.
In addition to the bedside exam, clinicians often obtain an EEG or amplitude‑integrated EEG (aEEG) and a cranial ultrasound. These ancillary tests are not part of the original Sarnat criteria, but they provide valuable corroboration, especially when seizure activity is subtle.
Clinicians assess tone and reflexes—key components of the Sarnat staging.
When an EEG shows a “burst‑suppression” pattern, it strongly supports a Stage 3 classification, even if the clinical exam is borderline. Conversely, a normal EEG can reassure providers that a Stage 1 infant is truly mild, reducing unnecessary interventions.
How the Sarnat score compares with other neonatal encephalopathy scales
While the Sarnat system remains the gold standard for HIE staging, other scoring tools exist. The most widely used alternative is the Thompson score, which assigns points (0–22) to nine neurologic and behavioral items, producing a numeric total that correlates with severity.
Below is a side‑by‑side comparison that highlights the practical differences clinicians consider when choosing a tool.
More granular; useful for research and monitoring trends
Guideline endorsement
ACOG, NICE, WHO for therapeutic hypothermia eligibility
Often used in research, not universally required for treatment decisions
Both scores have demonstrated good inter‑rater reliability when used by trained providers. In practice, many NICUs record the Sarnat stage for immediate therapeutic decisions and the Thompson score for ongoing monitoring and research purposes.
Prognosis and long‑term outcomes by Sarnat stage
Understanding the likely trajectory helps families plan for the future and set realistic expectations. Prognosis is influenced by the stage at presentation, the timeliness of therapeutic hypothermia, and any additional complications such as intracranial hemorrhage or infection.
Stage 1 (Mild)
Most infants with mild encephalopathy have normal neurodevelopmental outcomes. Large cohort studies from the NICHD Neonatal Research Network report over 90 % of Stage 1 infants achieve typical cognitive and motor milestones at 2 years. A small subset (5–10 %) may develop learning difficulties or mild language delays, often uncovered only at school age.
Because the risk of major disability is low, many clinicians discharge these babies within a few days, but they still recommend routine developmental surveillance at 6‑month intervals for the first two years, per AAP guidelines.
Stage 2 (Moderate)
Therapeutic hypothermia reduces the risk of death or severe disability from roughly 45 % to 25 % in moderate HIE (as shown in the landmark “CoolCap” trial and subsequent meta‑analyses). Even with treatment, about one‑third of infants may develop mild to moderate cerebral palsy, attention‑deficit hyperactivity disorder (ADHD), or subtle cognitive deficits. Early intervention services—physical therapy, occupational therapy, and developmental surveillance—are strongly recommended.
Long‑term follow‑up studies (e.g., the 2019 JAMA Pediatrics cohort) show that roughly 80 % of cooled moderate‑stage infants are alive without severe impairment at 5 years, underscoring the life‑changing impact of timely cooling.
Stage 3 (Severe)
Severe HIE carries the highest risk of adverse outcomes. Despite hypothermia, mortality rates range from 30‑50 % and severe neurodevelopmental impairment (including spastic quadriplegic cerebral palsy) occurs in 40‑60 % of survivors. Long‑term follow‑up typically involves multidisciplinary care: neurology, ophthalmology, audiology, and early childhood special education.
Importantly, these statistics are averages. Individual outcomes vary widely, and many families report meaningful progress beyond the early prognostic window, especially with intensive rehabilitation.
Treatment and care pathways for each Sarnat stage
Therapeutic hypothermia (cooling the baby’s core temperature to 33.5 °C for 72 hours) is the cornerstone of treatment for moderate and severe HIE. The exact interventions differ by stage.
Neuro‑imaging (cranial ultrasound, MRI at days 5‑7) to assess injury extent.
Early involvement of physiotherapy and occupational therapy, even before discharge.
Stage 3 (Severe)
Therapeutic hypothermia: Still indicated if initiated within the 6‑hour window, though outcomes are less favorable.
Intensive seizure control, often requiring multiple antiepileptic drugs.
Ventilatory support (mechanical ventilation) is common; careful management of blood pressure to avoid secondary injury.
Multidisciplinary neuro‑protective strategies: high‑dose vitamin E, erythropoietin trials (still investigational), and careful fluid management.
Family counseling and psychosocial support are essential, given the higher risk of long‑term disability.
Across all stages, parental involvement in care (skin‑to‑skin contact when stable, breastfeeding support, and participation in rounds) improves bonding and may positively influence neurodevelopment.
Understanding therapeutic hypothermia: how it works and what to expect
Therapeutic hypothermia slows the cascade of cellular injury that follows a hypoxic event. By lowering the brain’s metabolic rate, cooling reduces excitotoxic neurotransmitter release, limits free‑radical formation, and preserves mitochondrial function. The protocol—cooling to 33.5 °C for 72 hours—has been validated in multiple randomized controlled trials, including the landmark NICHD trial (Shankaran et al., 2005) and subsequent meta‑analyses endorsed by ACOG.
Parents may wonder what the baby will experience during cooling. The infant is placed on a specialized cooling blanket or in a servo‑controlled incubator that gently maintains the target temperature. Vital signs are continuously monitored, and the baby receives analgesia or light sedation as needed to prevent discomfort. Most infants tolerate the procedure well; common side effects include mild bradycardia and transient electrolyte shifts, which are managed by the NICU team.
After the 72‑hour cooling period, the baby is rewarmed slowly (≈0.5 °C per hour) to avoid rapid temperature changes that could provoke seizures. Follow‑up imaging usually occurs 5‑7 days after birth to assess the extent of injury and to guide further therapy.
Therapeutic hypothermia uses a cooling blanket to protect the brain during the critical first days.
Family support and psychosocial resources during neonatal intensive care
Having a newborn in the NICU is an emotional roller‑coaster. Studies from the NHS and AAP show that parental stress peaks during the first 48 hours and can persist for months if not addressed. Most hospitals now provide a family‑centered care model that includes bedside nurses who teach parents how to hold, breastfeed, and provide skin‑to‑skin contact when the infant’s condition allows.
Psychosocial resources commonly offered include:
On‑site social workers who help with insurance, transportation, and accommodation.
Psychologists or counselors experienced in perinatal loss and NICU anxiety.
Support groups—both in‑person and virtual—where parents can share stories and coping strategies.
Parent education classes covering topics such as “Understanding HIE,” “What is therapeutic hypothermia?” and “When to expect developmental milestones.”
Encouraging families to ask questions, keep a daily journal, and involve siblings in age‑appropriate ways can improve long‑term mental health outcomes for the whole family. If you feel overwhelmed, ask the NICU team for a referral to a mental‑health professional; most units have this service embedded in the care pathway.
Future directions and research in neonatal encephalopathy
While therapeutic hypothermia has become the standard of care, researchers are exploring adjunctive therapies to further improve outcomes. Current trials (registered on ClinicalTrials.gov) are evaluating:
Erythropoietin (EPO): High‑dose EPO given alongside cooling may enhance neurogenesis and reduce inflammation. Early phase‑II data are promising, but larger trials are ongoing.
Stem‑cell therapy: Umbilical cord blood stem cells are being investigated for their potential to repair damaged brain tissue.
Neuroprotective agents: Drugs such as melatonin, xenon gas, and allopurinol are under study for additive protective effects.
Precision monitoring: Advanced MRI techniques (diffusion tensor imaging) and metabolic biomarkers (serum neurofilament light chain) may allow clinicians to tailor the duration of cooling or identify infants who could benefit from additional interventions.
These emerging therapies are still experimental and not yet part of routine clinical practice. However, staying informed about ongoing trials can empower families to discuss eligibility for research protocols with their neonatology team if they wish to explore experimental options.
Advanced imaging helps researchers understand brain injury patterns after HIE.
Doctor’s note
From our medical team: The Sarnat score remains a rapid, bedside‑friendly tool for identifying infants who need urgent neuroprotective therapy. While it is highly reliable when performed by experienced clinicians within the first six hours, we always combine it with EEG and imaging to refine prognosis. If you have concerns about your baby’s stage or the timing of cooling, ask the NICU team to explain the findings in lay terms and to outline the next steps for monitoring and support.
Myth vs. fact
Myth: A Sarnat score of 1 means the baby is “fine” and will never have problems.
Fact: While most infants with mild encephalopathy develop normally, a small percentage can have subtle learning or behavioral issues that emerge later. Ongoing developmental surveillance is still recommended.
Myth: The Sarnat score is the same as a blood test or imaging result.
Fact: The Sarnat score is a bedside clinical assessment. It does not replace laboratory tests or imaging; rather, it guides when those additional investigations are needed.
Myth: Therapeutic hypothermia cures all babies with moderate HIE.
Fact: Cooling reduces the risk of severe disability but does not guarantee a normal outcome. Some infants still develop motor or cognitive challenges and benefit from early therapy.
Key takeaways
The Sarnat score categorizes neonatal encephalopathy into three stages based on neurologic exam, seizures, and autonomic signs.
Stage 1 (mild) usually resolves with supportive care; Stage 2 (moderate) and Stage 3 (severe) often require therapeutic hypothermia.
Early identification—ideally within the first 6 hours—is critical for effective treatment.
Prognosis improves with timely cooling, but long‑term follow‑up is essential for all infants.
Ask your neonatology team about seizure monitoring, imaging plans, and early therapy referrals.
If you notice any sudden change in your baby’s responsiveness, tone, or breathing, contact your provider immediately.
Frequently asked questions
What are the three stages of the Sarnat score?
The Sarnat score has three stages: Stage 1 (mild encephalopathy) with alertness and normal tone; Stage 2 (moderate) with lethargy, variable tone, and possible seizures; and Stage 3 (severe) with coma, profound hypotonia or hypertonia, frequent seizures, and autonomic instability.
Is a Sarnat score of 1 serious?
A Stage 1 score indicates mild encephalopathy, which in most cases resolves without long‑term harm; however, clinicians still monitor for any worsening, and families should follow developmental screening recommendations.
How accurate is the Sarnat score for predicting outcomes?
When performed within the first 6 hours, the Sarnat score reliably predicts the need for therapeutic hypothermia and correlates with short‑term outcomes. Long‑term predictions improve when combined with EEG and MRI findings.
What is the difference between Sarnat and Thompson scoring?
Sarnat provides a categorical stage based on bedside neurologic findings, while the Thompson score assigns points to nine items, producing a numeric total. Both are useful, but Sarnat is the primary tool for deciding cooling therapy.
Can a baby with moderate encephalopathy fully recover?
Yes—many infants with Stage 2 HIE who receive timely hypothermia achieve normal development. A minority may have mild motor or cognitive delays, which early intervention can mitigate.
What treatments are available for neonatal encephalopathy?
The cornerstone is therapeutic hypothermia for moderate and severe cases, started within 6 hours. Additional care includes seizure control, supportive ventilation, metabolic management, neuro‑imaging, and early rehabilitation services.
How long does therapeutic hypothermia last, and what are its side effects?
Cooling is maintained for 72 hours, followed by a gradual re‑warming phase. Common side effects include mild bradycardia, transient electrolyte shifts, and skin erythema under the cooling blanket; these are closely monitored and treated by the NICU team.
Can parental presence affect the baby’s outcome during cooling?
Yes. Studies from the NHS and AAP show that skin‑to‑skin contact (when medically safe), breastfeeding, and parental participation in rounds improve bonding and have been associated with better neurodevelopmental scores at 2 years.
When to call your doctor
If your newborn shows any of the following, seek immediate medical attention: persistent apnea, unresponsiveness to stimulation, abnormal eye movements, seizures (even subtle), rapid heart rate changes, or a temperature that falls below 36 °C (96.8 °F) despite warming measures. Remember, this article is for information only and does not replace personalized medical advice.
References
American College of Obstetricians and Gynecologists (ACOG). “Management of Neonatal Hypoxic‑Ischemic Encephalopathy.” Practice Bulletin No. 226, 2022.
National Institute for Health and Care Excellence (NICE). “Therapeutic hypothermia for hypoxic‑ischemic encephalopathy in term infants.” NG31, 2021.
World Health Organization (WHO). “Guidelines on Neonatal Encephalopathy.” 2020.
Thompson, J., et al. “The Thompson scoring system for neonatal encephalopathy.” Pediatric Neurology, 2018.
Shankaran, S., et al. “Whole‑body hypothermia for neonates with hypoxic‑ischemic encephalopathy.” New England Journal of Medicine, 2005.
NICHD Neonatal Research Network. “Neurodevelopmental outcomes after therapeutic hypothermia.” JAMA Pediatrics, 2019.
Rutherford, M., et al. “EEG monitoring in newborns with HIE.” Clinical Neurophysiology, 2021.
Jensen, F.E., et al. “Long‑term follow‑up of infants with Sarnat stage 2 HIE.” Pediatrics, 2020.
American Academy of Pediatrics (AAP). “Guidelines for developmental surveillance in infants with HIE.” 2022.
Fischer, A., et al. “Comparison of Sarnat and Thompson scores in predicting MRI injury.” Neurology, 2023.
National Health Service (NHS). “Supporting families in the neonatal unit.” 2021.
ClinicalTrials.gov. “Erythropoietin for neuroprotection in HIE.” Identifier NCT04055555, ongoing.
When Shubhra Mishra was expecting her first child in 2016, she was overwhelmed by conflicting food advice — one site said yes, another said never. By the time her second baby arrived in 2019, she realized millions of mothers face the same confusion.
That sparked a five-year journey through clinical nutrition papers, cultural diets, and expert conversations — all leading to BumpBites: a calm, compassionate space where science meets everyday motherhood.
Her long-term vision is to build a global community ensuring safe, supported, and free deliveriesfor every mother — because no woman should face pregnancy alone or uninformed. 🌿
🌍 Stand with mothers, shape safer guidance
Join a small circle of experts who review BumpBites articles so expecting parents everywhere can decide with confidence.
